Transglutaminase-based chemo-enzymatic conjugation approach yields homogeneous antibody-drug conjugates
Bioconjug Chem. 2014 March 19
2014/02 - volume: 25 - pages: 569-78.
Anti-KIR antibody enhancement of anti-lymphoma activity of natural killer cells as monotherapy and in combination with anti-CD20 antibodies
Blood. 2014 Jan 30
2013/12 - volume: 123 - pages: 678-86.
A phase 1 trial of the anti-inhibitory KIR mAb IPH2101 for AML in complete remission
Blood. 2012 Nov 22
2012/10 - volume: 120 - pages: 4317-23.
A monoclonal antibody directed against a conformational epitope of the HIV-1 trans-activator (Tat) protein neutralizes cross-clade
J Biol Chem. 2012 Apr 6
2012/03 - volume: 287 - pages: 11942-50.
NK cell MHC class I specific receptors (KIR): from biology to clinical intervention
Curr Opin Immunol. 2012 Apr;24
2012/03 - volume: 24 - pages: 239-45.
IPH2101, a novel anti-inhibitory KIR antibody, and lenalidomide combine to enhance the natural killer cell versus multiple myeloma effect
Blood. 2011 Dec 8
2011/11 - volume: 118 - pages: 6387-91.
TLR3 as a biomarker for the therapeutic efficacy of double-stranded RNA in breast cancer
Cancer Res. 2011 Mar 1
2011/02 - volume: 71 - pages: 1607-14.
Natural killer cell-based therapies
F1000 Med Rep. 2011
2010/12 - volume: 3 - pages: 9.
[Proteomics and breast cancer: a search for novel diagnostic and theragnostic biomarkers]
Bull Cancer. 2010 Mar
2010/02 - volume: 97 - pages: 321-39.
In vivo tumor cell rejection induced by NK cell inhibitory receptor blockade: maintained tolerance to normal cells even in the presence of IL-2
Eur J Immunol - 2010 Mar
2010/02 - volume: 40 - pages: 813-23.
NK cell activation by KIR-binding antibody 1-7F9 and response to HIV-infected autologous cells in viremic and controller HIV-infected patients
Clin Immunol. 2010 Feb
2010/01 - volume: 134 - pages: 158-68.
Preclinical characterization of 1-7F9, a novel human anti-KIR receptor therapeutic antibody that augments natural killer-mediated killing of tumor cells
Blood. 2009 Sep 24
2009/08 - volume: 114 - pages: 2667-77.
Genetic and antibody-mediated reprogramming of natural killer cell missing-self recognition in vivo
Proc Natl Acad Sci U S A. 2009 Aug 4
2009/07 - volume: 106 - pages: 12879-84.
Monoclonal antibody 16D10 to the COOH-terminal domain of the feto-acinar pancreatic protein targets pancreatic neoplastic tissues
Mol Cancer Ther. 2009 Feb
2009/01 - volume: 8 - pages: 282-91.
Mouse CD146/MCAM is a marker of natural killer cell maturation
Eur J Immunol. 2008 Oct
2008/09 - volume: 38 - pages: 2855-64.
Human NK cell education by inhibitory receptors for MHC class I
Immunity. 2006 Aug
2006/07 - volume: 25 - pages: 331-42.
Immunophenotypic analysis of inflammatory breast cancers: identification of an 'inflammatory signature'
J Pathol. 2004 Mar
2004/02 - volume: 202 - pages: 265-73.
Involvement of inhibitory NKRs in the survival of a subset of memory-phenotype CD8+ T cells
Nat Immunol. 2001 May
2001/04 - volume: 2 - pages: 430-5.
Modulation of T-cell functions in KIR2DL3 (CD158b) transgenic mice
Blood. 1999 Oct 1
1999/09 - volume: 94 - pages: 2396-402.
Fine specificity of antibodies to poly(Glu60Ala30Tyr10) produced by hybrid cell lines
Proc Natl Acad Sci U S A. 1979 May
1979/04 - volume: 76 - pages: 2425-9.